Search

Your search keyword '"Jong, Koert P."' showing total 377 results
Start Over Author "Jong, Koert P." Language english
377 results on '"Jong, Koert P."'

1. Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation

Author

Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne-Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger-Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, and Kazemier, Geert

Published
2024
Full Text
View/download PDF

2. Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases

Author

Wesdorp, Nina J., Zeeuw, J. Michiel, Postma, Sam C. J., Roor, Joran, van Waesberghe, Jan Hein T. M., van den Bergh, Janneke E., Nota, Irene M., Moos, Shira, Kemna, Ruby, Vadakkumpadan, Fijoy, Ambrozic, Courtney, van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Engelbrecht, Marc R. W., Gerhards, Michael F., Grunhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S. L., van Lienden, Krijn P., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Marquering, Henk A., Stoker, Jaap, Swijnenburg, Rutger-Jan, Punt, Cornelis J. A., Huiskens, Joost, and Kazemier, Geert

Published
2023
Full Text
View/download PDF

4. Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Bond, Marinde J. G., Kuiper, Babette I., Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H. C., Engelbrecht, Marc R. W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas, Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F. M., Leclercq, Wouter K. G., Liem, Mike S. L., van Lienden, Krijn P., Molenaar, I. Quintus, Neumann, Ulf P., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Kazemier, Geert, May, Anne M., Punt, Cornelis J. A., and Swijnenburg, Rutger-Jan

Published
2023
Full Text
View/download PDF

6. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Author

Van Gulik, Thomas, Huiskens, Joost, Van Tinteren, Harm, Dejong, Cornelis H.C., Grünhagen, Dirk J., Patijn, Gijs A., Ruers, Theo J.M., Chapelle, Thiery, Hermans, John J., Leclercq, Wouter K.G., Valkenburg-van Iersel, Liselot B.J., Grootscholten, Cecile, Van Dodewaard-de Jong, Joyce M., Vincent, Jeroen, Houtsma, Danny, Los, Maartje, Den Boer, Marien, Trajkovic-Vidakovic, Marija, Van Voorthuizen, Theo, Koopman, Miriam, Vestjens, Johanneke H.M.J.V., Torrenga, Hans, Mekenkamp, Leonie J., Veldhuis, Gerrit Jan, Polee, Marco B., Dohmen, Serge E., Schut, Heidi, Vulink, Annelie J.E., Van Halteren, Henk K., Oulad Hadj, Jamal, Schiphorst, Pieter-Paul J.B.M., Hoekstra, Ronald, Bond, Marinde J G, Bolhuis, Karen, Loosveld, Olaf J L, de Groot, Jan Willem B, Droogendijk, Helga, Helgason, Helgi H, Hendriks, Mathijs P, Klaase, Joost M, Kazemier, Geert, Liem, Mike S L, Rijken, Arjen M, Verhoef, Cornelis, de Wilt, Johannes H W, de Jong, Koert P, Gerhards, Michael F, van Amerongen, Martinus J, Engelbrecht, Marc R W, van Lienden, Krijn P, Molenaar, I Quintus, de Valk, Bart, Haberkorn, Brigitte C M, Kerver, Emile D, Erdkamp, Frans, van Alphen, Robbert J, Mathijssen-van Stein, Daniëlle, Komurcu, Aysun, Lopez-Yurda, Marta, Swijnenburg, Rutger-Jan, and Punt, Cornelis J A

Published
2023
Full Text
View/download PDF

7. The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial

Author

Bolhuis, Karen, Bond, Marinde J.G., Van Amerongen, Martin J., Komurcu, Aysun, Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas M., Hermans, John J., De Jong, Koert P., Kazemier, Geert, Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, Neumann, Ulf P., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., May, Anne M., Punt, Cornelis J.A., and Swijnenburg, Rutger-Jan

Published
2023
Full Text
View/download PDF

9. Study Protocol PROMETHEUS: Prospective Multicenter Study to Evaluate the Correlation Between Safety Margin and Local Recurrence After Thermal Ablation Using Image Co-registration in Patients with Hepatocellular Carcinoma

Author

Oosterveer, Timo T. M., van Erp, Gonnie C. M., Hendriks, Pim, Broersen, Alexander, Overduin, Christiaan G., van Rijswijk, Carla S. P., van Erkel, Arian R., van der Meer, Rutger W., Tushuizen, Maarten E., Moelker, Adriaan, Meijerink, Martijn R., van Delden, Otto M., de Jong, Koert P., van der Leij, Christiaan, Smits, Maarten L. J., Urlings, Thijs A. J., Braak, Jeffrey P. B. M., Meershoek-Klein Kranenbarg, Elma, van Duijn-de Vreugd, Bianca, Zeijdner, Evelijn, Goeman, Jelle J., Fütterer, Jurgen J., Coenraad, Minneke J., Dijkstra, Jouke, and Burgmans, Mark C.

Published
2022
Full Text
View/download PDF

12. Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications

Author

Pranger, Bobby K., van Dam, Jacob L., Groen, Jesse V., van Eijck, Casper H., Koerkamp, Bas G., Bonsing, Bert A., Mieog, J.Sven D., Besselink, Marc G., Busch, Olivier R., Kazemier, Geert, de Jong, Koert P., de Kleine, Ruben H.J., Molenaar, I.Quintus, Stommel, Martijn W.J., Gerhards, Michael F., Coolsen, Marielle M.E., van Santvoort, Hjalmar C., van der Harst, Erwin, Klaase, Joost M., and de Meijer, Vincent E.

Published
2021
Full Text
View/download PDF

13. Lessons learned from site-specific sampling and biological half-life of IGFII and IIE(68-88) peptide: a case study.

Author

Muller Kobold, Anneke C., de Haan, Jacco J., Bokkers, Reinoud P.H., Ruiter, Simeon J.S., van den Heuvel, Marius C., Lentjes, Eef G.W.M., Touw, Daan J., and de Jong, Koert P.

Subjects
PEPTIDES, HEPATIC veins, RENAL veins, INSULIN-like growth factor-binding proteins, SOMATOMEDIN A
Abstract

This article presents a case study on non-islet cell tumor induced hypoglycemia (NICTH), a rare condition associated with mesenchymal tumors. The study focuses on a patient with metastatic solitary fibrous tumors (SFT) and severe hypoglycemic symptoms. The researchers measured levels of insulin-like growth factor (IGF)-II and IIE(68-88) peptide in various sampling sites, including the hepatic vein draining the largest SFT metastasis. They also measured these substances in peripheral venous blood samples taken at different timepoints after tumor resection to determine their half-life and correlate the levels with tumor size and clinical parameters. The findings provide insight into the contribution of liver metastases to hormone production and highlight the importance of site-specific sampling in understanding the metabolism of tumor cells. However, the study suggests that site-specific sampling may have limited value in identifying the dominant hormone-producing site in patients with SFT. [Extracted from the article]

Published
2024
Full Text
View/download PDF

14. Outcomes of Resectability Assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel

Author

Van Amerongen, M.J., Dejong, Cornelis HC., Gerhards, Michael F., Grunhagen, Dirk, Heijmen, Linda, Hermans, John J., Keijser, Astrid, Klaase, Joost M., Van Lienden, Krijn P, Molenaar, Quintus I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Swijnenburg, Rutger-Jan, van Tinteren, Harm, Huiskens, Joost, Bolhuis, Karen, Engelbrecht, Marc RW., De Jong, Koert P., Kazemier, Geert, Liem, Mike SL., Verhoef, Cornelis, de Wilt, Johannes HW., Punt, Cornelis JA., and van Gulik, Thomas M.

Published
2019
Full Text
View/download PDF

15. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Patients

Author

Versteijne, Eva, Suker, Mustafa, Groen, Jesse V., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Busch, Olivier R., de Hingh, Ignace H. J. T., de Jong, Koert P., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Verkooijen, Helena M., Van Eijck, Casper H., and van Tienhoven, Geertjan

Published
2022
Full Text
View/download PDF

20. The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment

Author

Wesdorp, Nina J., Bolhuis, Karen, Roor, Joran, van Waesberghe, Jan-Hein T. M., van Dieren, Susan, van Amerongen, Martin J., Chapelle, Thiery, Dejong, Cornelis H. C., Engelbrecht, Marc R. W., Gerhards, Michael F., Grunhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S. L., van Lienden, Krijn P., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Swijnenburg, Rutger-Jan, Punt, Cornelis J. A., Huiskens, Joost, and Kazemier, Geert

Published
2021
Full Text
View/download PDF

21. Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial

Author

Bolhuis, Karen, Grosheide, Lodi, Wesdorp, Nina J., Komurcu, Aysun, Chapelle, Thiery, Dejong, Cornelis H. C., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas M., Huiskens, Joost, De Jong, Koert P., Kazemier, Geert, Klaase, Joost M., Liem, Mike S. L., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Punt, Cornelis J. A., and Swijnenburg, Rutger-Jan

Published
2021
Full Text
View/download PDF

22. Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit

Author

Van Gulik, Thomas M., Festen, Sebastiaan, Karsten, Tom M., Coene, Peter P., van Rijssen, Lennart B., Zwart, Maurice J., van Dieren, Susan, de Rooij, Thijs, Bonsing, Bert A., Bosscha, Koop, van Dam, Ronald M., van Eijck, Casper H., Gerhards, Michael F., Gerritsen, Josephus J., van der Harst, Erwin, de Hingh, Ignace H., de Jong, Koert P., Kazemier, Geert, Klaase, Joost, van der Kolk, Berendina M., van Laarhoven, Cornelis J., Luyer, Misha D., Molenaar, Isaac Q., Patijn, Gijs A., Rupert, Coen G., Scheepers, Joris J., van der Schelling, George P., Vahrmeijer, Alexander L., Busch, Olivier R.C., van Santvoort, Hjalmar C., Groot Koerkamp, Bas, and Besselink, Marc G.

Published
2018
Full Text
View/download PDF

24. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit

Author

Bollen, Thomas L., Bruno, Marco J., van Tienhoven, Geert-Jan, Norduyn, Arnold, Berry, David P., Tingstedt, Bobby, Tseng, Jennifer F., Wolfgang, Christopher L., van Rijssen, L. Bengt, Koerkamp, Bas G., Zwart, Maurice J., Bonsing, Bert A., Bosscha, Koop, van Dam, Ronald M., van Eijck, Casper H., Gerhards, Michael F., van der Harst, Erwin, de Hingh, Ignace H., de Jong, Koert P., Kazemier, Geert, Klaase, Joost, van Laarhoven, Cornelis J., Molenaar, I. Quintus, Patijn, Gijs A., Rupert, Coen G., van Santvoort, Hjalmar C., Scheepers, Joris J., van der Schelling, George P., Busch, Olivier R., and Besselink, Marc G.

Published
2017
Full Text
View/download PDF

25. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Author

Schnitzbauer, Andreas A., Filmann, Natalie, Adam, René, Bachellier, Philippe, Bechstein, Wolf O., Becker, Thomas, Bhoori, Sherrie, Bilbao, Itxarone, Brockmann, Jens, Burra, Patrizia, Chazoullières, Olivier, Cillo, Umberto, Colledan, Michele, Duvoux, Christoph, Ganten, Tom M., Gugenheim, Jean, Heise, Michael, van Hoek, Bart, Jamieson, Neville, de Jong, Koert P., Klein, Christian G., Klempnauer, Jürgen, Kneteman, Norman, Lerut, Jan, Mäkisalo, Heikki, Mazzaferro, Vincenzo, Mirza, Darius F., Nadalin, Silvio, Neuhaus, Peter, Pageaux, George-Philippe, Pinna, Antonio D., Pirenne, Jaques, Pratschke, Johann, Powel, James, Rentsch, Markus, Rizell, Magnus, Rossi, Giorgio, Rostaing, Lionel, Roy, André, Scholz, Tim, Settmacher, Utz, Soliman, Thomas, Strasser, Simone, Söderdahl, Gunnar, Troisi, Roberto I., Turrión, Victor Sánchez, Schlitt, Hans J., and Geissler, Edward K.

Published
2020
Full Text
View/download PDF

32. Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External Validation

Author

Mungroop, Timothy H., van Rijssen, L. Bengt, van Klaveren, David, Smits, F. Jasmijn, van Woerden, Victor, Linnemann, Ralph J., de Pastena, Matteo, Klompmaker, Sjors, Marchegiani, Giovanni, Ecker, Brett L., van Dieren, Susan, Bonsing, Bert, Busch, Olivier R., van Dam, Ronald M., Erdmann, Joris, van Eijck, Casper H., Gerhards, Michael F., van Goor, Harry, van der Harst, Erwin, de Hingh, Ignace H., de Jong, Koert P., Kazemier, Geert, Luyer, Misha, Shamali, Awad, Barbaro, Salvatore, Armstrong, Thomas, Takhar, Arjun, Hamady, Zaed, Klaase, Joost, Lips, Daan J., Molenaar, I. Quintus, Nieuwenhuijs, Vincent B., Rupert, Coen, van Santvoort, Hjalmar C., Scheepers, Joris J., van der Schelling, George P., Bassi, Claudio, Vollmer, Charles M., Steyerberg, Ewout W., Abu Hilal, Mohammed, Groot Koerkamp, Bas, and Besselink, Marc G.

Published
2019
Full Text
View/download PDF

35. A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making.

Author

Veenstra, Emile B., Ruiter, Simeon J. S., de Haas, Robbert J., de Jong, Koert P., Erba, Paola A., Dierckx, Rudi A. J. O., and Noordzij, Walter

Subjects
DECISION making, POSITRON emission tomography, PATIENT decision making, TUMOR markers, COMPUTED tomography, BIOMARKERS
Abstract

Background: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. Results: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. Conclusions: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases

Author

Wesdorp, Nina J, Kemna, Ruby, Bolhuis, Karen, van Waesberghe, Jan H T M, Nota, Irene M G C, Struik, Femke, Oulad Abdennabi, Ikrame, Phoa, Saffire S K S, van Dieren, Susan, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk, van Gulik, Thomas M, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Liem, Mike S L, van Lienden, Krijn P, Molenaar, I Quintus, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Swijnenburg, Rutger-Jan, Punt, Cornelis J A, Huiskens, Joost, Stoker, Jaap, Kazemier, Geert, Surgery, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Internal medicine, Radiology and nuclear medicine, AGEM - Re-generation and cancer of the digestive system, VU University medical center, CCA - Imaging and biomarkers, Radiology & Nuclear Medicine, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Radiology and Nuclear Medicine, AGEM - Digestive immunity, APH - Methodology, Oncology, Groningen Institute for Organ Transplantation (GIOT), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Value, Affordability and Sustainability (VALUE)

Subjects
Colorectal Neoplasms/diagnostic imaging, Male, Tumor Response, Abdomen/Gastrointestinal, Tomography, X-Ray Computed/methods, Observer Performance, Metastases, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Liver Neoplasms/diagnostic imaging, Humans, Prospective Studies, Tomography, Original Research, Computer. Automation, Observer Variation, Liver Neoplasms, General Medicine, Middle Aged, X-Ray Computed/methods, Liver, Oncology, Female, Human medicine, Colorectal Neoplasms, Tomography, X-Ray Computed, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], CT
Abstract

Item does not contain fulltext Purpose To evaluate interobserver variability in the morphologic tumor response assessment of colorectal liver metastases (CRLM) managed with systemic therapy and to assess the relation of morphologic response with gene mutation status, targeted therapy, and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 measurements. Materials and Methods Participants with initially unresectable CRLM receiving different systemic therapy regimens from the randomized, controlled CAIRO5 trial (NCT02162563) were included in this prospective imaging study. Three radiologists independently assessed morphologic tumor response on baseline and first follow-up CT scans according to previously published criteria. Two additional radiologists evaluated disagreement cases. Interobserver agreement was calculated by using Fleiss κ. On the basis of the majority of individual radiologic assessments, the final morphologic tumor response was determined. Finally, the relation of morphologic tumor response and clinical prognostic parameters was assessed. Results In total, 153 participants (median age, 63 years [IQR, 56-71]; 101 men) with 306 CT scans comprising 2192 CRLM were included. Morphologic assessment performed by the three radiologists yielded 86 (56%) agreement cases and 67 (44%) disagreement cases (including four major disagreement cases). Overall interobserver agreement between the panel radiologists on morphology groups and morphologic response categories was moderate (κ = 0.53, 95% CI: 0.48, 0.58 and κ = 0.54, 95% CI: 0.47, 0.60). Optimal morphologic response was particularly observed in patients treated with bevacizumab (P = .001) and in patients with RAS/BRAF mutation (P = .04). No evidence of a relationship between RECIST 1.1 and morphologic response was found (P = .61). Conclusion Morphologic tumor response assessment following systemic therapy in participants with CRLM demonstrated considerable interobserver variability. Keywords: Tumor Response, Observer Performance, CT, Liver, Metastases, Oncology, Abdomen/Gastrointestinal Clinical trial registration no. NCT02162563 Supplemental material is available for this article. © RSNA, 2022.

Published
2022

40. Preoperative Characteristics of Patients with Presumed Pancreatic Cancer but Ultimately Benign Disease: A Multicenter Series of 344 Pancreatoduodenectomies

Author

Gerritsen, Arja, Molenaar, I. Quintus, Bollen, Thomas L., Nio, C. Yung, Dijkgraaf, Marcel G., van Santvoort, Hjalmar C., Offerhaus, G. Johan, Brosens, Lodewijk A., Biermann, Katharina, Sieders, Egbert, de Jong, Koert P., van Dam, Ronald M., van der Harst, Erwin, van Goor, Harry, van Ramshorst, Bert, Bonsing, Bert A., de Hingh, Ignace H., Gerhards, Michael F., van Eijck, Casper H., Gouma, Dirk J., Borel Rinkes, Inne H. M., Busch, Olivier R. C., Besselink, Marc G., and Dutch Pancreatic Cancer Group

Published
2014
Full Text
View/download PDF

41. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Author

Geissler, Edward K., Schnitzbauer, Andreas A., Zülke, Carl, Lamby, Philipp E., Proneth, Andrea, Duvoux, Christophe, Burra, Patrizia, Jauch, Karl-Walter, Rentsch, Markus, Ganten, Tom M., Schmidt, Jan, Settmacher, Utz, Heise, Michael, Rossi, Giorgio, Cillo, Umberto, Kneteman, Norman, Adam, René, van Hoek, Bart, Bachellier, Philippe, Wolf, Philippe, Rostaing, Lionel, Bechstein, Wolf O., Rizell, Magnus, Powell, James, Hidalgo, Ernest, Gugenheim, Jean, Wolters, Heiner, Brockmann, Jens, Roy, André, Mutzbauer, Ingrid, Schlitt, Angela, Beckebaum, Susanne, Graeb, Christian, Nadalin, Silvio, Valente, Umberto, Turrión, Victor Sánchez, Jamieson, Neville, Scholz, Tim, Colledan, Michele, Fändrich, Fred, Becker, Thomas, Söderdahl, Gunnar, Chazouillères, Olivier, Mäkisalo, Heikki, Pageaux, Georges-Philippe, Steininger, Rudolf, Soliman, Thomas, de Jong, Koert P., Pirenne, Jacques, Margreiter, Raimund, Pratschke, Johann, Pinna, Antonio D., Hauss, Johann, Schreiber, Stefan, Strasser, Simone, Klempnauer, Jürgen, Troisi, Roberto I., Bhoori, Sherrie, Lerut, Jan, Bilbao, Itxarone, Klein, Christian G., Königsrainer, Alfred, Mirza, Darius F., Otto, Gerd, Mazzaferro, Vincenzo, Neuhaus, Peter, and Schlitt, Hans J.

Published
2016
Full Text
View/download PDF

43. Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices

Author

Martinec, Ondrej, Biel, Carin, de Graaf, Inge A.M., Huliciak, Martin, de Jong, Koert P., Staud, Frantisek, Cecka, Filip, Olinga, Peter, Vokral, Ivan, Cerveny, Lukas, Pharmaceutical Technology and Biopharmacy, Cancer Research Center Groningen (CRCG), Groningen Institute for Organ Transplantation (GIOT), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
EXPRESSION, CLINICAL-RELEVANCE, INDUCTION, CACO-2, IN-VITRO, GP ACTIVITY, P-glycoprotein (ABCB1 protein), rifampicin, TRANSPORTERS, human precision-cut intestinal slices, pregnane X receptor, BLOOD-MONONUCLEAR-CELLS, ABSORPTION, induction, absorption, DRUG-DRUG INTERACTIONS
Abstract

P-glycoprotein (ABCB1), an ATP-binding cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug–drug interactions. Drug-mediated induction of intestinal ABCB1 is a clinically relevant phenomenon associated with significantly decreased drug bioavailability. Currently, there are no well-established human models for evaluating its induction, so drug regulatory authorities provide no recommendations for in vitro/ex vivo testing drugs’ ABCB1-inducing activity. Human precision-cut intestinal slices (hPCISs) contain cells in their natural environment and express physiological levels of nuclear factors required for ABCB1 induction. We found that hPCISs incubated in William’s Medium E for 48 h maintained intact morphology, ATP content, and ABCB1 efflux activity. Here, we asked whether rifampicin (a model ligand of pregnane X receptor, PXR), at 30 μM, induces functional expression of ABCB1 in hPCISs over 24- and 48-h incubation (the time to allow complete induction to occur). Rifampicin significantly increased gene expression, protein levels, and efflux activity of ABCB1. Moreover, we described dynamic changes in ABCB1 transcript levels in hPCISs over 48 h incubation. We also observed that peaks of induction are achieved among donors at different times, and the extent of ABCB1 gene induction is proportional to PXR mRNA levels in the intestine. In conclusion, we showed that hPCISs incubated in conditions comparable to those used for inhibition studies can be used to evaluate drugs’ ABCB1-inducing potency in the human intestine. Thus, hPCISs may be valuable experimental tools that can be prospectively used in complex experimental evaluation of drug–drug interactions.

Published
2021

44. Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer

Author

Gerritsen, Arja, Bollen, Thomas L., Nio, Yung C., Molenaar, Quintus I., Dijkgraaf, Marcel G.W., van Santvoort, Hjalmar C., Offerhaus, Johan G., Brosens, Lodewijk A., Biermann, Katharina, Sieders, Egbert, de Jong, Koert P., van Dam, Ronald M., van der Harst, Erwin, van Goor, Harry, van Ramshorst, Bert, Bonsing, Bert A., de Hingh, Ignace H., Gerhards, Michael F., van Eijck, Casper H., Gouma, Dirk J., Borel Rinkes, Inne H.M., Busch, Olivier R.C., and Besselink, Marc G.H.

Published
2015
Full Text
View/download PDF

45. Comparison of Two 2.45 GHz Microwave Ablation Devices with Respect to Ablation Zone Volume in Relation to Applied Energy in Patients with Malignant Liver Tumours.

Author

Ruiter, Simeon J. S., de Jong, Jamila E., Pennings, Jan Pieter, de Haas, Robbert J., and de Jong, Koert P.

Subjects
RESEARCH, RELATIVE medical risk, LIVER tumors, METASTASIS, RETROSPECTIVE studies, TREATMENT effectiveness, COMPARATIVE studies, COLORECTAL cancer, STATISTICAL correlation, ABLATION techniques, HEPATOCELLULAR carcinoma
Abstract

Simple Summary: Ablation zone volumes (AZV) after microwave ablation (MWA) of malignant liver tumours remain highly unpredictable. The aims of the present study were to compare two 2.45 GHz MWA devices with respect to AZV in relation to the applied energy after MWA in patients with hepatocellular carcinoma or colorectal liver metastasis, and to identify potential confounders for this relationship. We confirmed the unpredictability of AZVs based on the applied output energy for both tumour types. We observed no differences in the ratio between AZV and the applied energy between tumour types. The ratio between AZV and applied energy was different between the two MWA devices; however, its reflected energy due to differences in cable and antenna design remains unclear and might contribute to these differences. Purpose: (i) to compare two 2.45 GHz MWA devices with respect to AZV in relation to the applied energy after MWA in patients with hepatocellular carcinoma (HCC) or colorectal liver metastasis (CRLM) and (ii) to identify potential confounders for this relationship. Methods: In total, 102 tumours, 65 CRLM and 37 HCC were included in this retrospective analysis. Tumours were treated with Emprint (n = 71) or Neuwave (n = 31) MWA devices. Ablation treatment setting were recorded and applied energy was calculated. AZV and tumour volumes were segmented on the contrast-enhanced CT scans obtained 1 week after treatment. The AZV to applied energy R(AZV:E) ratios were calculated for each tumour treatment and compared between both MWA devices and tumour types. Results: R(AZV:E)EMPRINT was 0.41 and R(AZV:E)NEUWAVE was 0.81, p < 0.001. Moderate correlation between AZV and applied energy was found for Emprint (r = 0.57, R2 = 0.32, p < 0.001) and strong correlation was found for Neuwave (r = 0.78, R2 = 0.61, p < 0.001). R(AZV:E)CRLM was 0.45 and R(AZV:E)HCC was 0.52, p = 0.270. Conclusion: This study confirms the unpredictability of AZVs based on the applied output energy for HCC and CRLM. No significant differences in R(AZV:E) were observed between CRLM and HCC. Significantly lower R(AZV:E) was found for Emprint devices compared to Neuwave; however, reflected energy due to cable and antenna design remains unclear and might contribute to these differences. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Distinct responses between healthy and cirrhotic human livers upon lipopolysaccharide challenge: possible implications for acute-on-chronic liver failure.

Author

Suriguga, Su, Mei Li, Luangmonkong, Theerut, Boersema, Miriam, de Jong, Koert P., Oosterhuis, Dorenda, Gorter, A. R., Beljaars, Leonie, and Olinga, Peter

Subjects
LIVER failure, LIPOPOLYSACCHARIDES, LIVER, LIVER transplantation, CIRRHOSIS of the liver
Abstract

Patients with acute-on-chronic liver failure (ACLF) are at risk of developing acute hepatic decompensation and organ failures with an unraveled complex mechanism. An altered immune response toward insults in cirrhotic compared with healthy livers may contribute to the ACLF development. Therefore, we aim to investigate the differences in inflammatory responses between cirrhotic and healthy livers using human precision-cut liver slices (PCLSs) upon the lipopolysaccharide (LPS) challenge. PCLSs prepared from livers of patients with cirrhosis or healthy donors of liver transplantation were incubated ex vivo with or without LPS for up to 48 h. Viability test, qRT-PCR, and multiplex cytokine assay were performed. Regulation of the LPS receptors during incubation or with LPS challenge differed between healthy versus cirrhotic PCLSs. LPS upregulated TLR-2 in healthy PCLSs solely (P < 0.01). Culturing for 48 h induced a stronger inflammatory response in the cirrhotic than healthy PCLS. Upon LPS stimulation, cirrhotic PCLSs secreted more proinflammatory cytokines (IL-8, IL-6, TNF-a, eotaxin, and VEGF) significantly and less antiinflammatory cytokine (IL-1ra) than those of healthy. In summary, cirrhotic PCLSs released more proinflammatory and less antiinflammatory cytokines after LPS stimuli than healthy, leading to dysregulated inflammatory response. These events could possibly resemble the liver immune response in ACLF. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results